

Substitute PTO/SB/08A (07-05)

Approved for use through 07/01/2005. OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
(Modified)**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket Number	186563/US/2 (469390-00352)
-------	---	----	---	------------------------	----------------------------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1	US-3,654,090	04-04-1972	Schuurs		
A2	US-3,850,752	11-26-1974	Schuurs et al.		
A3	US-4,016,043	04-05-1977	Schuurs et al.		
A4	US-4,341,761	07-27-1982	Ganfield et al.		
A5	US-4,399,121	08-16-1983	Altarelli et al.		
A6	US-4,427,783	01-24-1984	Newman et al.		
A7	US-4,444,887	04-24-1984	Hoffmann		
A8	US-4,451,570	05-29-1984	Royston et al.		
A9	US-4,466,917	06-02-1984	Nussenzweig et al.		
A10	US-4,472,500	09-18-1984	Milstein et al.		
A11	US-4,491,632	01-01-1985	Wands et al.		
A12	US-4,493,795	01-15-1985	Nestor et al.		
A13	US-4,493,890	01-15-1985	Morris		
A14	US-5,625,048	04-29-1997	Tsien et al.		
A15	US-5,777,079	07-07-1998	Tsien et al.		
A16	US-5,891,646	04-06-1999	Barak et al.		
A17	US-6,066,476	05-23-1990	Tsien et al.		
A18	US-6,110,693	08-29-2000	Barak et al.		
A19	US-RE 31,006	08-03-1982	Schuurs et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ⁴ Number ⁵ Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁷
	B1					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and country where published.	T ⁷
C1	ANGERS, S., et al.	"Detection β_2 -adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET)," Proc. Natl. Acad. Sci. USA 97(7):3684-3689 (Mar. 2000).	

Examiner Signature	/Zachary Howard/	Date Considered	04/23/2008

*EXAMINER: * These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.58(d). Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of coverage by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

4833-9489-7408II

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
(Modified)**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

		Complete if Known
Application Number	10/543,122	
Filing Date	January 26, 2004	
First Named Inventor	SHENOY, Sudha	
Art Unit	To be assigned	
Examiner Name	To be assigned	
	Attorney Docket Number	
	186563/US/2 (469390-00352)	

NON PATENT LITERATURE DOCUMENTS

Examiner Initiator	Cite No. [†]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data (page(s), volume-issue numbers), publisher, city and country where published.	T [‡]
	C2	CLAING, A., et al., "β-Arrestin-mediated ADP-ribosylation factor 6 activation and β ₂ -adrenergic receptor endocytosis," <i>J. Biol. Chem.</i> 276(45):42509-42513 (Nov. 2001) (first pub'd online 08/30/2001).	
	C3	CONG, M., et al., "Binding of the β ₂ adrenergic receptor to N-ethylmaleimide-sensitive factor regulates receptor recycling," <i>J. Biol. Chem.</i> 276(48):45145-45152 (Nov. 2001) (first pub'd online 09/27/2001).	
	C4	EDGE, M., et al., "Total synthesis of a human leukocyte interferon gene," <i>Nature</i> 292(5825):756-762 (Aug. 1981).	
	C5	GOVERS, R., et al., "Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor," <i>EMBO J.</i> 18(1):28-36 (Jan. 1999).	
	C6	HERSHKO, A., et al., "The ubiquitin system," <i>Annu. Rev. Biochem.</i> 67:425-479 (1998).	
	C7	HICKE, L., et al., "Ubiquitination of a yeast plasma membrane receptor signal its ligand-stimulated endocytosis," <i>Cell</i> 84(2):277-287 (Jan. 1996).	
	C8	JAY, E., et al., "Chemical synthesis of a biologically active gene for human immune interferon-γ. Prospect for site-specific mutagenesis and structure-function studies," <i>J. Biol. Chem.</i> 259(10):6311-6317 (May 1984).	
	C9	KRUPNICK, J., et al., "Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus," <i>J. Biol. Chem.</i> 272(23):15011-15016 (Jun. 1997).	
	C10	LAPORTA, S., et al., "The β ₂ -adrenergic receptor/barrestin complex recruits the clathrin adaptor AP-2 during endocytosis," <i>Proc. Natl. Acad. Sci. USA</i> 96(7):3712-3717 (Mar. 1999).	
	C11	LEFKOVITZ, R., "G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization," <i>J. Biol. Chem.</i> 273(30):18657-18680 (Jul. 1998).	
	C12	LUTTRELL, L., et al., "β-arrestin-dependent formation of β ₂ adrenergic receptor-Src protein kinase complexes," <i>Science</i> 283(5402):655-661 (Jan. 1999).	
	C13	LUTTRELL, L., et al., "Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds," <i>Proc. Natl. Acad. Sci. USA</i> 98(5):2449-2454 (Feb. 2001) (first pub'd online 02/20/2001).	
	C14	MORI, S., et al., "Identification of ubiquitin-ligation system for the epidermal-growth-factor receptor-herbimycin A induces in vitro ubiquitination in rabbit-reticulocyte lysate," <i>Eur. J. Biochem.</i> 247(3):1190-1196 (Aug. 1997).	
	C15	MORI, S., et al., "Degradation process of ligand-stimulated platelet-derived growth factor β-receptor involves ubiquitin-proteasome proteolytic pathway," <i>J. Biol. Chem.</i> 270(49):29447-29452 (Dec. 1995).	
	C16	NAMBIAR, K., et al., "Total synthesis and cloning of a gene coding for the ribonuclease S protein," <i>Science</i> 223(4642):1299 (Mar. 1984).	
	C17	NIMAN, H., et al., "Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition," <i>Proc. Natl. Acad. Sci. USA</i> 80(16):4949-4953 (Aug. 1983).	
	C18	NOREN, C., et al., "A general method for site-specific incorporation of unnatural amino acids into proteins," <i>Science</i> 244(4901):182-188 (Apr. 1989).	
	C19	OAKLEY, R., et al., "Differential affinities of visual arrestin, Barrestin1, and Barrestin2 for G protein-coupled receptors delineate two major classes of receptors," <i>J. Biol. Chem.</i> 275(22):17201-17210 (Jun. 2000).	

Examiner Signature	/Zachary Howard/	Date Considered	04/23/2008
*EXAMINER: [†] These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.58(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

[‡]Applicant's unique citation designation number (optional). [§] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [¶] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ^{**} For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ^{**} Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ^{*}Applicant is to place a check mark here if English Language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including time for reading, filling out, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-766-9199) and selection option 2

Substitute PTO/SB/08A (07-05)
 Approved for use through 07/31/2008. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
 (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/543,122
Filing Date	January 26, 2004
First Named Inventor	SHENOY, Sudha
Art Unit	To be assigned
Examiner Name	To be assigned

Attorney Docket Number 186563/US/2 (469390-00352)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C20	OAKLEY, R., et al., "Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-β-arrestin complexes after receptor endocytosis," <i>J. Biol. Chem.</i> 276(22):19452-19460 (Jun. 2001) (first pub'd online 03/09/2001).	
	C21	PERRY, S., et al., "Arresting developments in heptahelical receptor signaling and regulation," <i>Trends Cell Biol.</i> 12(3):130-138 (Mar. 2002).	
	C22	PHONPHOK, Y., et al., "Stabilization of clathrin coated vesicles by amantadine, tromantadine and other hydrophobic amines," <i>FEBS Lett.</i> 281(1-2):188-190 (Apr. 1991).	
	C23	ROTH, A., et al., "Ubiquitination of the yeast a-factor receptor," <i>J. Cell. Biol.</i> 134(3):661-674 (Aug. 1996).	
	C24	SHENOY, S., et al., "Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin," <i>Science</i> 294(5545):1307-1313 (Mar. 2001) (first pub'd online 10/04/2001).	
	C25	TOHGO, A., et al., "β-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation," <i>J. Biol. Chem.</i> 277(11):9429-9436 (Mar. 2002) (first pub'd online 01/02/2002).	
	C26	WANG, C., et al., "TAK1 is a ubiquitin-dependent kinase of MKK and IKK," <i>Nature</i> 412(6844):346-351 (Jul. 2001).	
	C27	WANG, Y., et al., "Down-regulation of protease-activated receptor-1 is regulated by sorting nexin 1," <i>Mol. Biol. Cell</i> 13(6):1965-1976 (Jun. 2002).	
	C28	ZHENG, B., et al., "RGS-PX1, a GAP for Gα _s and sorting nexin in vesicular," <i>Science</i> 294(5548):1939-1942 (Nov. 2001).	

Examiner Signature

/Zachary Howard/

Date Considered

04/23/2008

*EXAMINER: ¹ These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including an estimate of the time for review of the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2.

4833-9489-74081

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./